Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in Pregnant Women With Hepatitis C
NCT07040319Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2026
- Primary completion
- Mar 2028
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of glecaprevir, pibrentasvir in hepatitis C (HCV), sponsored by National Institute of Allergy and Infectious Diseases. Started Jun 2026; status: recruiting.
02
Drugs
glecaprevirpibrentasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT07040319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07040319.